Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2000
10/25/2000CN1271342A Synthesis of clasto-lactacystin-beta-lactone and analogs thereof
10/25/2000CN1271341A Substituted 2-pyrolidinone activators of PKC
10/25/2000CN1271338A Processes and intermediates useful to make antifolates
10/25/2000CN1271284A Vitronectin receptor antagonist
10/25/2000CN1271275A Small particle liposome aerosols for delivery of atni-cancer drugs
10/25/2000CN1270958A Beta-lactan
10/25/2000CN1057760C Amino acid substituted benzoylguanidines, process for their preparation, their use and medicament containing them
10/25/2000CN1057691C Chinese medicine for anti lung cancer and preparation process thereof
10/25/2000CN1057690C Chinese patent medicine for curing oophoroma
10/25/2000CN1057683C Method for preparing selenic-garlic compound medicine
10/24/2000US6137003 Bis (haloethyl) aminobenzene derivatives
10/24/2000US6136989 Adding acetone to paclitaxel extract to form acetone mixture; contacting acetone mixture with aqueous solvent to form precipitate; recovering precipitate
10/24/2000US6136988 7-hexanoyltaxol and methods for preparing the same
10/24/2000US6136978 Camptothecin analogs and methods of preparation thereof
10/24/2000US6136846 In water miscible solubilizer
10/24/2000US6136845 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl PCDFs
10/24/2000US6136839 Using a sulfone or sulfoamide benzene compound
10/24/2000US6136808 Antitumor agents from plants
10/24/2000US6136800 Steroids
10/24/2000US6136797 Phospholipid derivatives of phosphono-carboxylic acids, the production of said derivatives and the use of said derivatives as antiviral medicaments
10/24/2000US6136792 Prostate specific enhancer polynucleotides and methods of use thereof
10/24/2000US6136791 Viricides and anticarcinogenic agents
10/24/2000US6136790 Carbohydrate mimetics having antiadhesive properties
10/24/2000US6136787 Interleukin 1β protease and interleukin 1β protease inhibitors
10/24/2000US6136780 Administering naltrexone or naloxone to treat gastrointestinal cancer, particularly colon or pancreatic cancer
10/24/2000US6136603 Oligonucleotides which target the untranslated region of a cytokine receptor gene; for treatment of eosinophil defects such as asthma, rhinitis and dermatitis; wound healing agents; antiinflammatory agents; anticarcinogenic agents
10/24/2000US6136563 With defined substitutions for enhanced affinity for its receptor
10/24/2000US6136336 JM216 formulations
10/24/2000US6136332 Dermatological/pharmaceutical compositions comprising volatile oils/phenylated silicone oils
10/24/2000US6136315 Compositions and methods using complexes of heat shock protein 70 and antigenic molecules for the treatment and prevention of neoplastic diseases
10/24/2000US6136313 Processes and intermediates for synthetic antibody derivatives
10/24/2000US6136311 Using monoclonal antibodies
10/24/2000US6136310 Recombinant anti-CD4 antibodies for human therapy
10/24/2000US6136307 Reovirus for the treatment of cellular proliferative disorders
10/24/2000US6136306 Treatment of a mammalian patient having a tumor by administering to the patient allogenic donor lymphocytes that have been co-cultured in the presence of the patient-derived lymphocytes under conditions sufficient to alloactivate the
10/24/2000CA2194226C Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
10/24/2000CA2139664C Covalent polar lipid-peptide conjugates for biological targeting
10/20/2000CA2306355A1 Methods and compositions for treating human cells
10/19/2000WO2000062071A1 Diagnostic and therapeutic use of antibodies against the urokinase receptor
10/19/2000WO2000062067A1 Novel transduction molecules and methods for using same
10/19/2000WO2000062063A1 Methods for the diagnosis and treatment of metastatic prostate tumors
10/19/2000WO2000061788A2 Poly(dipeptide) as a drug carrier
10/19/2000WO2000061779A1 49 human secreted proteins
10/19/2000WO2000061774A2 Bone morphogenic proteins
10/19/2000WO2000061772A2 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
10/19/2000WO2000061766A2 Telomerase-specific cancer vaccine
10/19/2000WO2000061757A1 Tumor necrosis factor homologs and nucleic acids encoding the same
10/19/2000WO2000061756A2 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
10/19/2000WO2000061754A2 Human proteins and polynucleotides encoding them
10/19/2000WO2000061753A2 Compositions and methods for the treatment and diagnosis of breast cancer
10/19/2000WO2000061751A1 REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING EXPRESSION OF GENES REGULATED BY p21
10/19/2000WO2000061750A2 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
10/19/2000WO2000061748A1 48 human secreted proteins
10/19/2000WO2000061746A1 13 transmembrane protein expressed in prostate cancer
10/19/2000WO2000061635A2 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
10/19/2000WO2000061628A1 49 human secreted proteins
10/19/2000WO2000061627A1 49 human secreted proteins
10/19/2000WO2000061625A1 48 human secreted proteins
10/19/2000WO2000061624A1 48 human secreted proteins
10/19/2000WO2000061622A2 Genes associated with diseases of the kidney
10/19/2000WO2000061620A1 49 human secreted proteins
10/19/2000WO2000061617A2 Transiently immortalized cells for use in gene therapy
10/19/2000WO2000061612A2 Compounds and methods for therapy and diagnosis of lung cancer
10/19/2000WO2000061609A2 Prodrugs of thrombin inhibitors
10/19/2000WO2000061602A1 Antisense oligonucleotide modulation of stat3 expression
10/19/2000WO2000061597A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
10/19/2000WO2000061596A1 50 human secreted proteins
10/19/2000WO2000061595A1 The novel antisense-oligos with better stability and antisense effect
10/19/2000WO2000061590A1 Process for preparing amine platinum complexes
10/19/2000WO2000061587A1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
10/19/2000WO2000061585A2 1,3-dipolar cycloadditions to polypyrrolic macrocycles
10/19/2000WO2000061584A1 IMPROVED β,β,-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, AND BACTERIOCHLORINS
10/19/2000WO2000061583A1 Xanthine derivatives and analogs as cell signaling inhibitors
10/19/2000WO2000061581A1 Amine derivatives
10/19/2000WO2000061580A1 Substituted bicyclic heteroaryl compounds as integrin antagonists
10/19/2000WO2000061579A1 New endothelin converting enzyme inhibitors, their production and their use
10/19/2000WO2000061578A1 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
10/19/2000WO2000061571A1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
10/19/2000WO2000061555A1 Indigoid bisindole derivatives
10/19/2000WO2000061551A2 Pyrimidine-2-one derivatives as integrin receptor ligands
10/19/2000WO2000061546A2 Novel aryl-chloro-ethyl ureas
10/19/2000WO2000061545A1 Methods for solid phase combinatorial synthesis of integrin inhibitors
10/19/2000WO2000061543A2 Esters of l-carnitine or alkanoyl l-carnitines
10/19/2000WO2000061542A1 Caspase inhibitors and the use thereof
10/19/2000WO2000061191A2 Heat stable coated colloidal iron oxides
10/19/2000WO2000061189A2 Water-soluble compositions of bioactive lipophilic compounds
10/19/2000WO2000061187A1 Radioenhanced cancer treatment using orally administered camptothecin derivatives
10/19/2000WO2000061185A1 Docetaxel in combination with rhumab her2 for the treatment of cancers
10/19/2000WO2000061184A2 Dry formulation for transcutaneous immunization
10/19/2000WO2000061183A2 Verotoxin treatment of lymphomas
10/19/2000WO2000061180A2 Products and methods for treating ptp lar related diseases
10/19/2000WO2000061175A2 Use of pegylated interferon alpha in melanoma therapy
10/19/2000WO2000061174A2 Use of pegylated interferon alpha for renal cell carcinoma treatment
10/19/2000WO2000061173A2 Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy
10/19/2000WO2000061172A1 Interferon-beta use in the treatment of ewing's family of tumors
10/19/2000WO2000061167A2 TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
10/19/2000WO2000061162A1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
10/19/2000WO2000061159A1 MEDICAMENT FOR INHIBITING NF-λB
10/19/2000WO2000061153A1 Medicinal compositions and their method of preparation
10/19/2000WO2000061150A1 Antisense modulation of fas mediated signaling
1 ... 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 ... 2211